Royalty Pharma Plc (RPRX) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Royalty Pharma Plc  (NASDAQ: RPRX)


Royalty Pharma Plc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Royalty Pharma Plc's ROI in the third quarter of 2026?
Royalty Pharma Plc achieved a return on average invested assets (ROI) of 4.13 % in its third quarter of 2026, this is above RPRX's average return on investment of -52.17%.
Royalty Pharma Plcs investments during the 12 months ending in the third quarter of 2026 are valued at $22 billion

ROI fell compared to the second quarter of 2026, despite the net income growth of 77.55% from the second quarter of 2026.

Within the Healthcare sector 140 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Sep 30 2026 quarter, so far to 1476, from total ROI ranking in the second quarter of 2026 at 1889.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM 6.38 % 9.54 % 8.17 % 4.9 % 3.35 %
Y / Y Net Income Change TTM -16.19 % -34.75 % -36.55 % -15.49 % 34.45 %
Investment (TTM) in Millions 21,341 22,142 22,328 22,223 22,023
Return On Investment (TTM) 4.13 % 4.73 % 4.57 % 4.56 % 5.24 %
RPRX's Overall Ranking # 1476 # 1889 # 1352 # 779 #
Seq. Investment Change TTM -0.77 % 1.49 % 3.31 % 2.24 % 2.17 %
Seq. Net Income Change TTM -13.31 % 4.94 % 3.61 % -11.08 % -32.51 %
Net Income (TTM) in Millions 909 1,048 999 964 1,084

RPRX Company Profile >> Back to RPRX Roi Comparisons >> See Annual RPRX Return On Investment



Return On Investment RPRX's Ranking
Within: No.
Industry # 50
Sector # 141
Overall # 1476

Return On Investment Statistics
High Average Low
11.77 %
-52.17 %
-417.9 %
(Sep 30 2020)   (Sep 30 2017)







Financial Statements
Royalty Pharma Plc's III. Quarter Investments $ 21,341 Millions RPRX's Balance sheet
Royalty Pharma Plc's III. Quarter Income $ 145 Millions Quarterly RPRX's Income Statement
RPRX's Income by Division See RPRX's Income by Division


RPRX Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 22,223 20,365 19,778 19,544 21,817
Y / Y Investment Growth 9.12 % 2.97 % 1.2 % -10.42 % 4.94 %
Net Income in Millions 1,324 1,331 1,700 230 1,241
Y / Y Net Income Growth -0.5 % -21.72 % 638.96 % -81.46 % -27.07 %
Annual Return On Investment 5.96 % 6.53 % 8.6 % 1.18 % 5.69 %


Annual Roi Comment
In the fiscal year 2025 ROI decreased relative to the previous year to 5.96 %, due to deterioration of net income.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
RPRX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for RPRX's Competitors
Subscribers only: Roi for Royalty Pharma Plc's Suppliers
Subscribers only: Return On Investment for RPRX's Customers

Other Ratios
RPRX's Roa RPRX's Inventory Turnover Ratio RPRX's Growth Rates RPRX's Dividend Statistics
RPRX's Profitability Ratios RPRX's Asset Turnover Ratio RPRX's Dividend Growth
RPRX's Roe RPRX's Valuation Ratios RPRX's Financial Strength Ratios RPRX's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Bioventus Inc   11.26 %
Tenet Healthcare Corp  10.91 %
Bio rad Laboratories Inc   10.59 %
Lemaitre Vascular Inc   10.56 %
Johnson and Johnson  10.53 %
Encompass Health Corporation  10.41 %
Ani Pharmaceuticals Inc  9.61 %
Tactile Systems Technology Inc   9.27 %
Boston Scientific Corporation  9.14 %
Brightspring Health Services Inc   9.01 %
Stryker Corp  8.63 %
Pediatrix Medical Group Inc   8.37 %
Penumbra Inc  8.28 %
Medinotec Inc   8.12 %
Pacific Health Care Organization Inc  8.09 %
Quest Diagnostics Inc  8.01 %
Ge Healthcare Technologies Inc   7.60 %
Incyte Corporation  6.81 %
Merit Medical Systems Inc  6.21 %
Davita Inc   6.13 %
Black Hawk Acquisition Corporation  6.10 %
Iqvia Holdings Inc   6.09 %
Labcorp Holdings Inc   6.07 %
Pacs Group Inc   5.95 %
Ensign Group Inc  5.94 %
Amneal Pharmaceuticals Inc   5.59 %
Sotera Health Company  5.43 %
Henry Schein Inc   5.27 %
Abbott Laboratories  5.14 %
Haemonetics Corporation  4.85 %

Date modified: 2026-11-06T13:04:08+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.